SOPHiA GENETICS And AstraZeneca Collaborate To Further Expand Global Access To Liquid Biopsy Testing; SOPHiA GENETICS Will Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM To 20 Locations Worldwide Over The Next 12 Months
SOPHiA GENETICS And AstraZeneca Collaborate To Further Expand Global Access To Liquid Biopsy Testing; SOPHiA GENETICS Will Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM To 20 Locations Worldwide Over The Next 12 Months
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months
這些公司承諾在未來12個月內將先進的液體活檢測試引入全球20家機構。
BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS powered with SOPHiA DDM, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (NASDAQ:AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS powered with SOPHiA DDM to 20 locations worldwide over the next 12 months.
2024年9月10日，美國波士頓和瑞士羅爾，智能遺傳學公司SOPHiA GENETICS（納斯達克：SOPH）與全球領先的數據驅動醫學公司SOPHiA GENETICS宣佈，MSk-ACCESS液體活檢試驗將在全球20個地點推广部署。該項目是在2023年10月首次宣佈的。根據與阿斯利康（納斯達克：AZN）的最終合作協議，SOPHiA GENETICS將在未來12個月內將帶動MSk-ACCESS液體活檢試驗攜手SOPHiA DDm技術在全球20個地點投入使用。
